New NASH drug shows promise in early trial
NCT ID NCT06297434
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called J2H-1702 in 87 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. The goal was to see if the drug is safe and if it can reduce liver fat and scarring after 12 weeks compared to a placebo. Participants were randomly assigned to receive either the drug or a dummy pill, and neither they nor their doctors knew which they got.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
J2H Biotech
Suwon, Gyeonggi-do, 16684, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test and AI could spot liver cancer early, saving lives
- Painless liver check: could a quick scan replace the needle?
- Computer nudge boosts liver referrals
- Healthy volunteers needed to test safety of experimental NASH drug
- Can genes predict liver cancer? new study seeks answers
- Researchers uncover key risk factors for severe NASH fibrosis